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Background: Heme oxygenase, cytochrome P450 reductase, and biliverdin reductase are the key enzymes in heme degradation.
Results: Specific electrostatic and hydrophobic interactions form the binding interface between heme oxygenase and cytochrome P450
reductase.
Conclusion: Heme oxygenase binds cytochrome P450 reductase dynamically and biliverdin reductase very weakly.
Significance: Characterizing interactions among proteins involved in heme degradation are crucial to understanding heme homeostasis.

Abstract
Heme oxygenase (HO) catalyzes the rate-limiting step in the O2dependent degradation of heme to biliverdin, CO, and iron with
electrons delivered from NADPH via cytochrome P450 reductase
(CPR). Biliverdin reductase (BVR) then catalyzes conversion of biliverdin to bilirubin. We describe mutagenesis combined with kinetic,
spectroscopic (fluorescence and NMR), surface plasmon resonance,
cross-linking, gel filtration, and analytical ultracentrifugation studies
aimed at evaluating interactions of HO-2 with CPR and BVR. Based
on these results, we propose a model in which HO-2 and CPR form
a dynamic ensemble of complex(es) that precede formation of the
productive electron transfer complex. The 1H-15N TROSY NMR
spectrum of HO-2 reveals specific residues, including Leu-201, near
the heme face of HO-2 that are affected by the addition of CPR, implicating these residues at the HO/CPR interface. Alanine substitutions at HO-2 residues Leu-201 and Lys-169 cause a respective 3and 22-fold increase in Km values for CPR, consistent with a role for
these residues in CPR binding. Sedimentation velocity experiments
confirm the transient nature of the HO-2·CPR complex (Kd = 15.1
μm). Our results also indicate that HO-2 and BVR form a very weak
complex that is only captured by cross-linking. For example, under
conditions where CPR affects the 1H-15N TROSY NMR spectrum of
HO-2, BVR has no effect. Fluorescence quenching experiments also
suggest that BVR binds HO-2 weakly, if at all, and that the previously
reported high affinity of BVR for HO is artifactual, resulting from the
effects of free heme (dissociated from HO) on BVR fluorescence.
Keywords: Cytochrome P450, Electron Transfer Complex, Enzyme
Kinetics, Enzyme Mechanism, Heme Oxygenase, Nuclear Magnetic
Resonance (NMR), Protein/Protein Interaction

P

recise regulation of heme metabolism is crucial for the cell.
Heme is an active catalyst for generating reactive oxygen
species by Fenton chemistry and is cytotoxic at elevated levels
(above ~1 μm) (1). Heme is also a required prosthetic group
for many proteins involved in electron transfer, oxygen transport, and redox enzymology (e.g. oxidases) (2). The mammalian heme degradation pathway consists of two enzymatic
steps, which are mediated by heme oxygenase (HO)4 and biliverdin reductase (BVR) (Figure 1). Cytochrome P450 reductase
(CPR) is required as an electron donor for HO catalysis. HO is
the only known catalyst in the mammalian cell that degrades
heme (Reaction 1). HO catalyzes the conversion of heme to
biliverdin in a reaction that requires O2, NADPH, and CPR,
which transfers seven electrons as shown in Reaction 1 (3, 4).
BVR then converts biliverdin to bilirubin (Reaction 2), which
undergoes conjugation with glucuronate and is excreted from
the body.
heme + 7e– + 3O2 → biliverdin + CO + Fe(II) + 3H2O
Reaction 1

biliverdin + 2e– → bilirubin
Reaction 2
In addition to protecting the cell from the toxicity of free
heme, the heme degradation pathway generates biologically important products. The HO reaction is the only cellular
source of CO, and although high levels of CO are toxic (>500
ppm), at low levels, CO acts as a signaling molecule akin to

Abbreviations: HO, heme oxygenase; CPR, cytochrome P450 reductase; BVR, biliverdin reductase; TROSY, transverse relaxation-optimized spectroscopy; SPR, surface plasmon resonance; LC-SPDP, succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate; CPM, 7-diethylamino-3-(4′-maleimidylphenyl)-4methylcoumarin; CSP, chemical shift perturbation; Ni-NTA, nickel-nitrilotriacetic acid; PDB, Protein Data Bank; SPR, surface plasmon resonance

29836

p rot e i n / p rot e i n i n t e r a c t i o n s i n t h e m a m m a l i a n h e m e d e g r a dat i o n pat h way

29837

Figure 1. Heme degradation pathway. The two enzymatic steps of heme degradation mediated by heme oxygenase and biliverdin reductase. HO converts
heme to biliverdin, and BVR converts biliverdin to bilirubin. The HO reaction requires electrons transferred from NADPH via cytochrome P450 reductase (PDB
1AMO, 2QPP, and 2H63).

NO (5, 6) and is cytoprotective (7). The release and recycling of
iron from heme is critical for iron homeostasis as most of the
iron required for the synthesis of new ferroproteins and heme
comes from recycled iron, with less than 3% of the daily iron
requirement derived from the diet (2, 8). Finally, the HO system protects cells against oxidative stress, both by controlling
free heme levels and by producing bilirubin, a potent antioxidant (9–11).
The heme degradation pathway affects many areas of cellular health as follows: heme and iron homeostasis, antioxidant
protection, and gaseous signaling. As such, it is crucial to understand the mechanisms that regulate the activity of HO.
HO exists as two major isoforms, HO-1 and HO-2. HO-3
has also been described; however, it has low catalytic activity,
and its biologic role and relevance are uncertain (12, 13). HO-1
and HO-2 share a high degree of homology (55% identity and
76% similarity) and display similar enzymatic activity (14).
The two isoforms, however, have distinct patterns of expression and regulation. HO-1 is transcriptionally regulated and is
expressed in most tissues, whereas HO-2 is constitutively expressed in a narrow range of tissues, primarily the brain and
testes (15). Both HOs possess C-terminal membrane-spanning
regions that tether them to the endoplasmic reticulum. However, because of poor solubility of the full-length protein, most
enzymatic studies (as those described in this paper) have been
conducted with a stable soluble form of HO lacking the C-terminal region. A major difference between the two HOs is that
HO-2 contains three heme regulatory motifs, consisting of a
Cys-Pro dyad, whereas HO-1 completely lacks cysteines (16).
Two of these heme regulatory motifs are at the C terminus of
HO-2, just preceding the membrane-spanning section. When
these are in the dithiol state, the affinity of HO-2 for heme (relative to the disulfide state) decreases significantly, suggesting that the heme regulatory motifs act as a redox switch that
controls activity in response to changes in cellular redox poise
(17–19).
Electrons are transferred to HO from NADPH via the ~77kDa dual flavin enzyme CPR through a pathway that involves
its bound cofactors, FAD and FMN (20–23). In the cell, CPR is
tethered to the endoplasmic reticulum by an N-terminal membrane-spanning region. Protein/protein interactions between
the soluble forms of HO-1 and CPR and between HO-1 and
BVR have been described in vitro (24–27) and are an aspect
of regulation that has not been addressed for HO-2. CPR also
forms electron transfer complexes with the cytochromes P450,

cytochrome b5, cytochrome c, and squalene monooxygenase
(23, 28–31). Interactions with CPR may help define distinct
roles for the HO isoforms. For example, recent reports suggest
that binding of HO-1 and CPR regulates HO-1 nuclear translocation and the transcriptional regulatory response under hypoxia by stabilizing the endoplasmic reticulum-tethered form
of HO-1 in the cell (32). However, HO-2 appears to remain stably associated at the endoplasmic reticulum irrespective of hypoxic challenge (32).
The complex between the soluble forms of CPR and HO-1
(lacking their membrane-spanning regions) has been characterized by fluorescence quenching (27), surface plasmon resonance (SPR) (24), and acetylation protection assays (25). These
reports provide Kd values for the HO-1· CPR complex that
range from 0.4 ± 0.1 to 2.4 ± 0.6 μm. CPR protects lysine residues 149 and 153 in HO-1 from chemical modification, suggesting that these basic residues are at the interface of the HO1· CPR complex (25). Additionally, SPR studies indicate that
the K149A substitution results in an ~10-fold increase in Kd for
the HO-1· CPR complex (24). Although the HO-1· CPR complex has been relatively well characterized, the HO-2· CPR
complex has not.
BVR catalyzes the second step in heme degradation, i.e. the
reduction of biliverdin to bilirubin (Reaction 2). BVR is a soluble ~33-kDa protein that utilizes two electrons from either
NADH or NADPH making it unique to have dual cofactor
specificity at distinct pH values (33). In addition to its canonical enzymatic function, BVR has also been shown to bind and
traffic heme to the nucleus where it regulates HO-1 expression
(34–37). Also, BVR is a dual specificity (Ser/Thr and Tyr) kinase, and as such it is implicated in mitogen-activated protein
kinase (MAPK) cell signaling pathways (38, 39).
Two groups have reported interactions between HO-1 and
BVR via fluorescence quenching studies and SPR (24, 27). The
fluorescence quenching studies suggest a high affinity HO1·BVR complex (Kd = 0.2 μM) is formed, whereas SPR studies report that BVR competes with CPR for binding to HO-1.
However, studies that identified the HO-1/CPR interface via
lysine acetylation protection assays failed to find evidence for
an HO-1/BVR interaction (25). Under single turnover conditions, the rate-limiting step of the HO-1 reaction is the release
of biliverdin; however, in the presence of BVR, this step is accelerated (40), which indicates kinetic coupling between these
two enzymes. Thus, although some evidence supports the formation of a high affinity complex between HO-1 and BVR,
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other evidence challenges it. Furthermore, to our knowledge,
the extent to which HO-2 is able to interact with BVR has not
been addressed. Protein/protein interactions between HO and
its reaction partners may play an important role in regulating
its various properties, including cellular localization and enzymatic activity. Furthermore, given that they exhibit different modes of transcriptional regulation, HO-1 and constitutive
HO-2 may differ in their affinity for BVR and CPR.
To gain insight into the protein level mode of regulating
HO-2 activity, and to resolve some of the discrepancies related
to measured interactions (or lack thereof) of HO-1 and HO-2
with their binding partners, we have performed nuclear magnetic resonance (NMR), kinetic, analytical ultracentrifugation,
gel filtration, cross-linking, SPR, and fluorescence quenching
studies. Our experiments indicate that both HO-1 and HO-2
form complexes with CPR. The interaction between HO-2 and
BVR, however, is weak as compared with CPR, and it can only
be detected by irreversible methods such as cross-linking. Our
results allow us to propose an interface for the HO-2· CPR
complex near the heme-binding face of HO-2 that includes residues Leu-201 and Lys-169. Furthermore, our studies demonstrate that the HO/CPR interface includes both hydrophobic
and charge interactions. Our studies suggest a reinterpretation
of protein/protein interactions in the heme degradation pathway. We demonstrate that both HO-1 and HO-2 bind CPR in
a transient electron transfer complex that is required for HO
activity. However, interactions between BVR and HO-2 are
weak to undetectable and may not play a significant role in the
physiologic context of a cell.
Experimental Procedures
Materials — Ampicillin, isopropyl β-d-thiogalactopyrano
side, kanamycin, NADPH, NADP+, riboflavin, and hemin
were purchased from Sigma. 7-Diethylamino-3-(4′-maleimi
dylphenyl)-4-methylcoumarin (CPM) was purchased from
Molecular Probes, Inc. (Eugene, OR). OneShot® BL21(DE3)
chemically competent cells were purchased from Invitrogen.
Nickel-nitrilotriacetic acid (NTA) resin was from Qiagen (Valencia, CA). Glutathione-Sepharose was purchased from GE
Healthcare.
Enzymes — Truncated versions of human HO-1265 containing residues 1–265, and human HO-2288 containing residues
1–288, and variants of these enzymes, were used in these studies. These enzymes lack the C-terminal amino acids that comprise their membrane anchors and will be referred to as HO-1
and HO-2. To facilitate expression, solubility, and ease of purification, HO-1 was cloned into the expression vector pMCSG10
by ligation-independent cloning (41). HO-2 was expressed and
purified from the pET28a(+) vector. HO-1 and HO-2 were purified via an N-terminal His6 tag using Ni-NTA affinity chromatography according to the manufacturer’s guidelines (Qiagen, Valencia, CA).
Human CPRΔ66 lacking the N-terminal membrane anchor
was expressed from the pET28a(+) vector and is referred to
as CPR for all studies described herein. CPR was expressed in
BL21(DE3) cells and purified according to published methods
(42). Human BVR was expressed from the pGEX-4T-2 vector
and purified via glutathione-Sepharose affinity resin according to the manufacturer’s instructions (GE Healthcare).
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Unless stated otherwise, affinity purification tags were removed from all proteins by proteolysis before use in these experiments. Tobacco etch virus protease (expressed in Escherichia coli from pRK793, a derivative of BL21(DE3)-RIL,
generously supplied by Dr. David S. Waugh at the Center for
Cancer Research at NCI, National Institutes of Health) was
used for HO-1, and thrombin was used for HO-2, CPR, and
BVR. The affinity tags were separated from the protein by
chromatography with the appropriate affinity resin (Ni-NTA
for HO-1, HO-2, and CPR; and glutathione-Sepharose for
BVR). All purification steps were performed at 4 °C.
The cDNA for human full-length HO-1 was graciously supplied by Dr. Ortiz de Montellano (University of California at
San Francisco). The ligation-independent cloning expression
vector pMCSG10 was donated by Dr. William Clay Brown
(University of Michigan, Ann Arbor). Human full-length HO-2
cDNA in a pGEX-4T-2 vector was generously contributed by
Dr. Mahin D. Maines (University of Rochester, School of Medicine, Rochester, NY) and was subcloned into the pET28a(+)
expression vector. CPR was kindly donated by Dr. Bettie Sue
Masters (University of Texas Health Sciences Center, Arlington, TX). The BVR gene was purchased from American Type
Culture Collection (Manassas, VA) and subcloned into the
pGEX-4T-2 plasmid.
Site-directed Mutagenesis of HO-1 and HO-2 — Point mutations
of HO-1 and HO-2 were constructed using the QuikChange
site-directed mutagenesis protocol (Stratagene, La Jolla, CA).
Oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA). Positive transformants were enriched
by antibiotic selection and confirmed using sequence analysis.
All of the variants were purified exactly as described above for
the wild type enzymes.
NMR Samples — BL21(DE3) cells containing the pET28a(+)/
HO-2 plasmid were cultured in M9 minimal media with 1.0
g/liter 15NH4Cl (Cambridge Isotopes, Tewksbury, MA) to
achieve 15N labeling of the soluble HO-2 protein. HO-2 was
purified as described above and loaded with heme by titration of freshly prepared hemin. Hemin stocks were prepared
by solubilizing hemin in 15% dimethyl sulfoxide (DMSO), 0.1
m NaOH, 50 mm Tris, pH 7.0. Hemin stocks were centrifuged
at 17,000 × g for 10 min at 4 °C, and the supernatant was then
passed through a 0.22-micron filter (Millipore, Billerica, MA)
to remove insoluble matter. Hemin concentration was determined using an Σ385 nm of 58.44 mm−1 (43). HO-2 was loaded
with hemin by titrating small amounts of hemin and monitoring the Soret peak at 404 nm until saturating levels of heme
binding were achieved. NMR samples were prepared with
150 μm heme-bound HO-2 in 50 mm Tris-HCl, pH 7.0, 50 mm
KCl with 10% D2O in a total volume of 350 μl and placed in a
Shigemi NMR tube. Experiments testing the ability of CPR or
BVR to bind HO-2 were conducted with 150 μm HO-2 and the
binding partner (BVR or CPR) at the indicated concentration.
1H-15N apoHO-2 NMR TROSY samples were prepared
identically to those described for hHO-2; however, heme was
absent from the samples.
For perdeuterated 15N-HO-2, samples were prepared as
described above; however, BL21(DE3) cells were grown and
induced in 2H2O/M9 minimal media. Electrospray ionization
mass spectrometry analysis revealed label incorporation to
be 99.8%.
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TROSY NMR Measurements — Two-dimensional 1HHSQC TROSY spectra were acquired on an Agilent/
Varian 800 MHz spectrometer equipped with a triple resonance gradient (PFG) cryoprobe operating at 30 °C. Spectra
were acquired using an array of 2404 × 300 complex points
and with the spectral widths of 12019.2 and 2999.9 Hz for
1H and 15N, respectively. All spectra were processed with
NMRPipe software (44) and visualized using Sparky 3.114
(45). Intensity analysis was conducted as described (46); the
peak heights of chemical shifts were derived from Sparky
and used to calculate the ratio of resonance height for the
1H-15N HO-2 spectrum with and without CPR or BVR. The
chemical shift perturbation (CSP) for the assigned crosspeaks was measured between the 0 μm CPR spectrum and
the 75 or 150 μm CPR spectrum for the perdeuterated 15NhHO-2 TROSY spectrum. CSPs were calculated from the
square root of the sum of the squared N1H and 15N CSPs for
each assigned cross-peak.
1H-15N

15N

NMR Relaxation —The experiments for studying the 15N
NMR relaxation of HO-2 were carried out using a 40 μm HO-2
sample that was 15N-labeled in 50 mm Tris-HCl, 50 mm KCl,
pH 7.0, and recorded at 30 °C on a Agilent/Varian 800 MHz
NMR system, using a cryoprobe.
One-dimensional versions of the standard 15N R1 and 15N
R2 HSQC experiments (with cross-correlation, but with without Rex suppression) were carried out (47). In these experiments, amide proton magnetization is transferred to the amide 15N, where it is allowed to decay according to 15N R1 or R2
relaxation mechanisms and transferred back to the amide proton for observation. R2 relaxation is faster for larger than for
smaller molecules; R1 relaxation is slower for larger than for
smaller molecules. From the ratio, one may calculate the rotational correlation time. For spherical, rigid proteins, the rotational correlation time is proportional to the molecular weight.
The data were processed in NMRpipe and exported in text
format using the Pipe2txt.tcl routine. The data were then imported into Microsoft Excel. For each spectrum, the ranges
8.7–9.0 ppm (structured core residues) were integrated, and
the data were fit to a single exponential decay curve using inhouse written nonlinear least square fit code with jackknife error estimation (48).
Steady-state Kinetic Analysis of HO-1, HO-2, and Variants — The HO
enzymatic assay was modified from methods described previously (49, 50). Recent studies establish that catalase enhances
the linearity of the membrane-bound HO-1-catalyzed reaction
(50). In our soluble system, we found a similar benefit of catalase for both HO-1 and HO-2 and therefore included it in the
enzymatic assays. The 200-μl reaction contained 0.1 μm HO,
15 μm heme, 0.35 μm BVR, 0.25 μg/μl BSA, 20 units/μl catalase, and varying concentrations of CPR in reaction buffer
(50 mm Tris-HCl, pH 8.0, 50 mm KCl). The reaction was incubated at 37 °C for 2 min and then initiated with the addition of
8 μl of 10 mm NADPH. Activity was monitored using a Shimadzu UV-2600 spectrophotometer by following the increase
in bilirubin absorbance at 468 nm. The difference extinction
coefficient between heme and bilirubin at 468 nm of 43 mm−1
cm−1 was used.
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Size Exclusion Chromatography — For gel filtration experiments,
proteins were dialyzed into buffer containing 50 mm Tris-HCl,
pH 7.0, 50 mm KCl. After recovery from the dialysis tubing,
samples were prepared with 50 μm of the indicated protein,
150 μm heme, and 150 μm NADP+. Gel filtration was conducted with a Shimadzu HPLC with an LC-10AT pump system using a Shodex KW-803 column (Shodex, Torrance, CA).
The column was calibrated using gel filtration standards (BioRad), and the void volume was determined using blue dextran
(2000 kDa, Sigma).
Surface Plasmon Resonance with HO and CPR — SPR binding experiments were conducted using a BIAcore 2000 (GE Healthcare) at 25 °C in 50 mm Tris, pH 7.0, 50 mm KCl with 0.005%
surfactant p20. HO-1 or HO-2 was immobilized directly to the
dextran matrix of a research grade CM5 sensor chip by amine
coupling according to the manufacturer’s instructions (GE
Healthcare). The sensor chip surface was activated with NHS/
EDC for 7 min. Immobilized proteins were diluted to 0.001
μg/μl with 10 mm sodium acetate, pH 4.5, and injected over
the sensor chip surface. To minimize nonspecific binding and
mass transfer, the immobilization levels were kept below 1000
response units. HO-1 and HO-2 were immobilized to 900 and
300 response units, respectively.
For kinetic analysis of CPR and HO, 45 μl of varying concentrations of CPR were injected at a flow rate of 20 μl/min.
Chip regeneration was conducted with a 5-μl injection of 0.5
mm NaCl. A blank reference cell was subtracted from the experimental data. To determine kinetic parameters, three independent experiments were initially analyzed using BIAevaluation software (GE Healthcare) and fit to a 1:1 Langmuir
binding model or a bivalent analyte model. Because these
models fit the data poorly, the association phase of CPR binding to HO was analyzed using single exponential fits (GraphPad 6.0). Kinetic constants were determined from the linear regression of kobs values plotted against CPR concentration.
For experiments with immobilized CPR, human CPR was
immobilized to the CM5 chip according to previously described methods for immobilization of rat CPR (24). Briefly,
CPR was immobilized via thiol groups of cysteine residues with the coupling reagent 2-(2-pyridinyldithio)ethaneamine). To stabilize the enzyme and protect residues near
the NADPH-binding site, NADPH was included during the
immobilization of CPR. CPR was immobilized to ~2000 response units. Others have reported that modification of CPR
by 2-(2-pyridinyldithio)ethaneamine) does not affect enzyme
activity (24). Binding analysis with immobilized CPR was performed identically to those described above, with freshly prepared hemin as the soluble analyte.
Sedimentation Velocity Analysis — Binding interactions between
HO-2 and CPR were analyzed by sedimentation velocity experiments using a method described previously (51). Sedimentation velocity experiments were performed on an Optima XL-I analytical ultracentrifuge (Beckman Coulter, Inc.)
equipped with an eight-hole An50Ti rotor. Prior to analysis,
HO-2 and CPR were dialyzed against 50 mm Tris, pH 8.0, containing 150 mm NaCl. CPR (20.5 μm) was then mixed with increasing concentrations of HO-2 (0–55 μm), and the resulting
protein mixtures (400 μl) were loaded into the sample compartment of a double-sector cell. The reference compartment
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was filled with 430 μl of the dialysate buffer. Sample cells were
then incubated at 20 °C in the rotor chamber for 2 h under vacuum. After 2 h of incubation, samples were sedimented at
40,000 rpm. A total of 180 absorbance scans (450 nm) at 3-min
intervals were collected. Absorbance values ranged from 0.2 to
0.8 for the different samples. The data were analyzed by SEDFIT version 10.58d (52) using the continuous c(s) distribution
model and allowing the frictional ratio to float. CPR-/HO-2 interactions were monitored by integrating the c(s) distribution
between 4 and 7 S to determine the weight-average s value of
the new observed boundary component (51). A Kd value for
the CPR·HO-2 complex was estimated by plotting the weightaverage s value as a function of HO-2 and fitting the data to a
single-site binding isotherm.
Chemical Cross-linking — The reducible, heterobifunctional
cross-linker (succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate) (LC-SPDP) was used in a two-step reaction according to the manufacturer’s instructions (Thermo
Scientific/Pierce). HO-1 or HO-2 was activated as follows. A
fresh 3 mm solution of LC-SPDP was prepared in DMSO. 10
μm HO-1 or HO-2 was prepared in conjugation buffer (0.1 m
HEPES), pH 7.5, 30 mm EDTA, 150 mm NaCl and incubated
with 0.1 mm LC-SPDP for 30 min at room temperature. Unconjugated cross-linker was then removed by three rounds
of buffer exchange using 10,000 molecular weight cutoff Amicon microconcentrators (Millipore, Billerica, MA). 10 μm
BVR, CPR, or RNase was then added to the activated protein,
and the reaction was incubated at 4 °C overnight. Cross-linking reactions were analyzed by 5–15% gradient sodium SDSPAGE (Bio-Rad) and visualized by staining the gel with Coomassie Blue (53).
Co-purification of BVR with HO-2 — For the co-purification of
BVR with HO-2, the cross-linking reaction was performed exactly as described above; however, HO-2 contained an N-terminal His6 tag (hisHO-2) that was absent in the other reactions. By SDS-PAGE, the cross-linked products of the reaction
containing hisHO-2 and BVR migrated to identical positions
as those in which the His6 tag had been removed from HO2. Samples of hisHO-2 alone, BVR alone, or cross-linked
hisHO-2/BVR were incubated with 100 μl of Ni-NTA resin
(50% slurry) for 2 h at 4 °C. Samples were rotated on a Boekel
variable speed mini-tube rotator (Fisher). Affinity resin and
associated proteins were harvested by centrifugation for 5
min at a setting of 2400 × g at 4 °C with an accuSpin Micro
17R refrigerated microcentrifuge (Fisher) and washed three
times with 1 ml of wash buffer (50 mm Tris-HCl, pH 8.0, 30
mm NaCl, 20 mm imidazole). Protein bound to the resin was
eluted with 50 mm Tris-HCl, pH 8.0, 30 mm NaCl, 300 mm imidazole. Eluted fractions were boiled for 5 min in SDS-PAGE
loading buffer (50 mm Tris-HCl, pH 6.8, 2% (w/v) SDS, 0.1%
(w/v) bromphenol blue, 10% (v/v) glycerol, and 100 mm dithiothreitol) and separated by 10% SDS-PAGE (53). Proteins
were then transferred to a nitrocellulose membrane and detected using antibodies against either HO-2 (18) or BVR (Abcam, Cambridge, MA).
Modification of BVR with CPM — Human BVR was modified with 7-diethylamino-3-(4′-maleimidylphenyl)-4-methyl
coumarin (CPM) according to methods used to modify rat
BVR (27). A 20 mm solution of CPM was prepared in dimethyl
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sulfoxide. 10 μm BVR with 1 mm NADPH was incubated in
the dark with 100 μm CPM at 4 °C for 16 h. Free CPM was
removed using a PD-10 desalting column (Amersham Biosciences). Labeled BVR was then frozen and stored in the dark at
−80 °C. BVR-CPM was analyzed by LC MS/MS to determine
the location of the CPM modification.
Fluorescence Resonance Energy Transfer (FRET) Analysis of the Interaction of HO-1 or HO-2 with BVR — FRET experiments to examine
HO-1 or HO-2 binding to human BVR were conducted according to previously described methods for rat BVR (27). Briefly,
because the UV-visible spectra of heme-bound HO-1 and
HO-2 overlap the fluorescence emission spectrum of the fluorescent probe CPM, binding of heme-bound HO should result
in fluorescence quenching of BVR-CPM. BVR-CPM (0.05 μm)
was titrated with various concentrations of heme-bound HO1, heme-bound HO-2, or heme, and fluorescence was monitored at 450 nm with excitation at 350 nm. These experiments
were performed in 0.1 m potassium phosphate buffer at pH
7.4 on a Shimadzu FR-5301PC spectrofluorophotometer.
Heme Binding BVR by Optical Absorbance — To obtain the absorbance spectrum of heme-BVR, the difference spectra between
350 and 700 nm were recorded for 2.5 μm BVR with 2.0 μm
heme, whereas the reference cuvette contained 2.5 μm BVR
alone. To determine binding affinity of heme for BVR, 10 μm
hemin was titrated with increasing amounts of BVR (0.5–5.0
μm) with 10 μm heme alone in the reference cuvette. Absorbance at 415 versus BVR concentration was fit to a single site
binding model using GraphPad Prism 6.0. To assess the ability
of BVR to bind heme from hHO-2, 5 μm of hHO-2 was incubated with varying concentrations of BVR (1.0–20.0 μm), and
the absorbance spectra from 250 to 700 nm was collected, with
the reference cuvette containing 5 μm hHO-2. hHO-2 was prepared by incubating apoHO-2 with a 5-fold excess of freshly
prepared hemin for 1 h at 4 °C. Unbound heme was removed
using a PD10 desalting column according to the manufacturer’s instructions (GE Healthcare). For all experiments fresh hemin was used and was prepared as described above. All spectra were collected on a Shimadzu UV-2600 spectrophotometer.
Results
Various forms of HO and CPR lacking their transmembrane segments were used in these studies. These are HO-1(1–
265) containing residues 1–265, HO-2(1–288), and CPR(66–
680). For clarity, these proteins will be referred to simply as
HO-1, HO-2, or CPR. In experiments that use heme-bound
HO, we refer to the protein as hHO-1 or hHO-2.
NMR Analysis of the Interaction between hHO-2 and CPR — NMR
is a highly sensitive method to probe protein/protein interactions. Binding of an NMR-silent protein to an NMR-visible protein can perturb the spectrum in several ways; it can
change the chemical shift, alter the line width of a resonance,
or affect both chemical shift and line width. If resonances
within the NMR spectrum have been assigned, these spectral
changes can provide residue-specific information regarding
the interface between the two proteins.
We recently assigned 70% of the backbone chemical shifts of the hHO-2 (heme-bound) NMR spectrum by
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Figure 2. NMR analysis of CPR binding hHO-2. 1H-15N TROSY spectra of 150 μm perdeuterated 15N-hHO-2 collected in the absence (black) or presence
(red) of equimolar CPR.

three-dimensional NMR experiments using a highly concentrated sample (1 mm).5 To avoid potential nonspecific interaction effects that could arise with highly concentrated protein, in the binding studies described here, we used 150 μm
15N hHO-2 samples. Because large proteins such as HO-2
(~33 kDa) tend to exhibit faster transverse relaxation that reduces signal intensity of the NMR spectrum, we utilized transverse relaxation-optimized spectroscopy (TROSY). TROSY is a
method that reduces the 1H and 15N resonance line widths to
enhance the spectra of larger proteins (>30 kDa) (54). By applying TROSY, we observe 211 cross-peaks in the 1H-15N TROSY
spectrum of perdeuterated 15N-hHO-2, which accounts for resonances arising from ~70% of the hHO-2 residues (Figure 2).
The hHO-2 spectrum consists of resonances arising from both
ordered and disordered regions of the protein. Amide proton resonances arising from disordered regions of HO-2 occur
in the 7.7–8.6 ppm range, which has a high density of overlapping peaks characteristic of poorly structured regions (46).
This region of the spectrum corresponds to the flexible N- and
C-terminal domains of hHO-2 residues 1–28 and 243–288. The
well dispersed peaks outside of the disordered region arise
from the core of hHO-2, as highlighted by the annotated spectra (Figure 2). (I. Bagai, S. W. Ragsdale, and E. R. P. Zuiderweg, manuscript in preparation.) Also, in the crystal structure of HO-2 (PDB 2QPP), only the catalytic core of the protein
(residues 29–242) is visible, and both the N and C termini are

not observed, further supporting the flexibility of the N and C
termini (55).
To probe the interface between hHO-2 and CPR, we collected the spectrum of perdeuterated 15N-hHO-2 in the presence or absence of natural abundance CPR (lacking any label).
As noted above, we used a lower concentration of hHO-2 (150
μm) than was used earlier to make the assignments to minimize the potential for nonspecific effects such as aggregation.
We overlaid the assigned HO-2 spectrum with that collected
in the binding studies to determine assignments for the spectrum in the binding studies. Using this method, ~50% of the
288 HO-2 residues in the binding study could be assigned.
Analysis of the HO-2 spectrum described below will focus on
the assigned region of the protein.
We measured the chemical shift and peak height for resonances in the hHO-2 TROSY spectrum in the presence and absence of CPR. To identify hHO-2 residues that are affected by
CPR, we compared the 1H-15N TROSY spectrum of hHO-2 in
the presence of equimolar unlabeled CPR with that of hHO-2
alone. The addition of CPR to hHO-2 causes changes in hHO-2
chemical shifts and also decreases in peak intensities for a
number of hHO-2 residues (Figure 2). This peak intensity loss
is consistent with an increase in molecular weight and concomitant reduction of TROSY intensity that we would expect
to occur as hHO-2 molecular weight increases with the binding of a 70-kDa protein such as CPR (46, 56).
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Figure 3. Effect of CPR on hHO-2 chemical shifts. Detail of the 1H-15N hHO-2 spectrum with 0, 75, or 150 μm CPR (black, blue, and red, respectively)
highlighting cross-peaks that experience significant perturbations of the chemical shift or significant intensity loss. Glu-182 and Asp-210 show highly significant
change in chemical shifts, although Leu-81 is broadened beyond detection with the addition of CPR. x represents the center of the indicated cross-peak. Highly
significant changes in CSP are greater than two standard deviations from the mean CSP for assigned residues.

The addition of CPR to hHO-2 also results in CSPs for some
hHO-2 cross-peaks (Figure 3). This demonstrates that the kinetics of binding is in the fast or intermediate fast exchange
for which the resonance position ωiobs of a certain residue i is
given by Equation 1 (57),
ωiobs = ffree ωifree + fbound ωibound

(1)

where ffree and fbound are the molar fractions of free and complexed HO-2, and where ωifree and ωibound are the chemical
shifts in radians of that resonance in those states. Equation 1
holds for both 1H and 15N dimensions in the TROSY spectrum.
To quantify CSPs, the 1H and 15N chemical shift difference
was calculated by comparing the chemical shifts of hHO-2
alone with those of CPR. The combined 15N/NH chemical
shift change was calculated as the chemical shift change vector as described under “Experimental Procedures.” Of the 47
assigned cross-peaks in the N and C termini, none exhibit significant CSPs with the addition of equimolar CPR; however,
28 residues from the HO-2 core exhibit significant CSPs (Figure 4). Mapping the residues with significant CSPs onto the
hHO-2 crystal structure highlights contiguous patches of residues on HO-2 that are likely involved in binding CPR or experience allosteric effects upon CPR binding (Figure 5). Equally
important, there are also many assigned resonances that do
not shift, and they also form contiguous patches.
For the range 0.1 < ffree or fbound < 0.9, the line width, LWiobs,
for a resonance i in the fast/intermediate exchange regime is
given by Equation 2 (57).
LWiobs = ffree LWifree + fbound LWibound
free
bound)2
+ ffree fbound (ωi – ωi
(1 + fbound/ ffree)koff

(2)

Here, the first two terms represent the increase in line
width due to a change in the time-averaged molecular weight
of HO-2, although the latter term, called exchange broadening,
is excess broadening due to the kinetics of binding.
The increase in line width causes a loss in TROSY crosspeak height by two processes as follows: the first is a linear
effect and occurs because a broader line in the spectrum has
a lower peak height; the second is a strongly nonlinear effect
due to a decrease in the coherence transfer efficiencies in the
TROSY experiment itself. For large proteins that bind to other
large proteins, the second effect is dominant.
To quantify the peak intensity loss in the hHO-2 spectrum
upon CPR binding, the peak intensity ratio was determined by
dividing the cross-peak intensity in the presence of CPR by the
cross-peak intensity from the hHO-2 alone spectrum (+CPR/−
CPR, Figure 6). A ratio of 1 indicates no effect, although a decreased ratio indicates line broadening for that resonance.
Cross-peaks derived from residues located at the HO-2 N and
C termini (residues 1–28 and 243–288) are largely unaffected
by the addition of equimolar CPR; of the 47 assigned crosspeaks, only four exhibit chemical shift intensity ratios of less
than 0.8 (Gly-20, Ala-245, and Glu-247). This is in contrast to
the 96 assigned cross-peaks located at the core of HO-2 (residues 29–242); 88 resonances exhibit an intensity ratio of less
than 0.8, and 23 have disappeared likely due to broadening beyond detection (Figure 6). Mapping the intensity ratios onto
the hHO-2 crystal structure shows the residues that are most
strongly affected by CPR are on the heme binding face of
hHO-2 (in which the heme binding pocket and surrounding
residues are visible), although residues on the opposite face
(180° rotation) of hHO-2 are less affected (Figure 7).
The interaction areas determined from intensity changes
(Figure 5) and chemical shift changes (Figure 7) do overlap in
general, suggesting the main binding area is identified by both
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Figure 4. Effect of CPR on hHO-2 chemical shifts. Histogram bars represent the combined 15N/NH chemical shift perturbation (CSP) for assigned residues
in the hHO-2 spectrum in the presence of 75 or 150 μm CPR (white or gray, respectively). The CSP for the assigned cross-peaks, measured between the 0 μm
CPR spectrum and the 75 or 150 μm CPR spectrum, was calculated from the square root of the sum of the squared N1H and 15N CSPs. Cross-peaks that have
broadened beyond detection with the addition of CPR are shown as black bars of uniform height. Dotted lines indicate CSPs that are significant (1 standard deviation from the mean) or very significant (2 standard deviations from the mean). Bars with gray labels represent resonances that are unassigned, and assigned residues are in black.

observables. However, the intensity changes and chemical
shifts do not correlate per residue. The most compelling case
occurs for the resonance of Leu-201, which completely disappears although it does not shift. As discussed below, this discrepancy indicates a complex binding mechanism.
Titration of CPR into hHO-2 by NMR — If the effects of CPR on the
hHO-2 spectrum are due to CPR binding, changes induced by
CPR should be titratable. Thus, additional experiments were
conducted with 50, 150, 200, and 300 μm CPR, and the resonance height ratio was calculated as described above (Figs. 8
and 9). Under these conditions, using hHO-2 that was not perdeuterated, we observed 165 cross-peaks in the 1H-15N hHO-2
spectrum, which accounts for resonances arising from ~60%
of the hHO-2 residues. Comparison of these spectra with the

assigned spectrum allows for assignment of 36% of 288 HO-2
residues (Figure 9).
To quantify the effects of CPR on hHO-2 residues, we compared the 1H-15N TROSY spectrum of hHO-2 in the presence
of CPR to that of hHO-2 alone. Although the addition of CPR
to hHO-2 does not cause observable changes in hHO-2 chemical shifts in the TROSY spectrum for non-perdeuterated hHO2, a decrease in peak intensity for a number of hHO-2 residues
proportional to the concentration of CPR is observed (Figure
9). Although titratable changes in the HO-2 spectrum could
conceivably result from CPR-dependent catalytic activity of
HO-2, this is unlikely to be the cause of the observed intensity changes because NADPH is not present in the NMR experiment and HO-2 is inactive in its absence. Furthermore,
CPR causes similar peak height reduction for the apoHO-2
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Figure 5. CPR-induced CSPs on the hHO-2 spectrum mapped onto
the crystal structure. The effect of 75 or 150 μm CPR (A and B, respectively) on hHO-2 CSPs as determined in Figure 4 was mapped onto the crystal structure of hHO-2 (PDB 2QPP). The color of the residue reflects the degree of CSP effect by CPR. Red indicates residues with highly significant CSPs
(more than two standard deviations from the mean); orange indicates residues with significant CSPs (at least one standard deviation from the mean);
blue indicates residues with no significant CSP; white indicates residues that
are broadened beyond detection; gray indicates residues that are unassigned.

spectrum, here substrate and reducing equivalents are both
absent, preventing any catalytic turnover.
Of the assigned residues in the hHO-2 spectrum, the residue that is most affected by the addition of equimolar concentrations of CPR is Leu-201. Glu-107, Ala-208, Leu-209, Leu211, and Leu-33 are also strongly affected. Although in our 150
μm NMR sample we do not have consecutive assignments for
these residues, in the more concentrated multidimensional experiments used for assigning the hHO-2 spectrum Leu-201,
Ala-208, Leu-209, and Leu-211 are part of a consecutively assigned region Glu-190–Asn-212. Leu-33 is part of a consecutively assigned region from Arg-29–Leu-37 and Glu-107 is part
of a consecutively assigned region from Glu-107–Leu-109, so
the assignments are quite secure.
We also conducted 15N T2 and T1 relaxation experiments to
estimate the molecular mass of hHO-2 under the NMR conditions. The rotational correlation time of a protein is linearly related to its molecular weight; therefore, 15N spin relaxation rates can be used to determine the molecular weight
of a protein in solution (58). The molecular mass estimate for
the hHO-2 core was found to be 55 kDa. The mass of monomeric hHO-2(1–288) is 33 kDa and that of the hHO-2 core (29–
242) is 25 kDa. Thus, the NMR relaxation experiments indicate
that hHO-2 is a dimer under the present conditions (>40 μm
protein).
NMR Analysis of the Interaction between apoHO-2 and CPR — To
test the ability of CPR to bind apoHO-2, the 1H-15N spectrum
of 500 μm non-perdeuterated 15N-apoHO-2 was collected in
the presence or absence of 100 μm CPR, as described for hHO2. The addition of CPR to apoHO-2 causes a loss of intensity
for apoHO-2 cross-peaks similar to what is observed in the
hHO-2 spectrum (Figure 10). In the apoHO-2 spectrum, 121
distinct cross-peaks are visible, representing ~40% of HO-2
residues. Although assignments for the apoHO-2 spectrum
have not been determined, changes in chemical shift intensity were quantified by calculating the chemical shift height
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ratio (+CPR/−CPR) for each of the cross-peaks. Of the 121 distinct cross-peaks analyzed in the apoHO-2 spectrum, 19 exhibit a chemical shift height ratio of less than 0.8, indicating a
loss of cross-peak height for the corresponding HO-2 residues.
Changes in chemical shift are not observed for any cross-peaks
in the non-perdeuterated spectra. These data indicate that CPR
is capable of binding apoHO-2 as well as hHO-2.
Assignments have not been independently determined
for the apoHO-2 TROSY spectrum, and the spectrum is distinct from that of hHO-2 (Figure 11). However, some isolated
cross-peaks of the hHO-2 spectrum have identical chemical
shifts as in the apoHO-2 spectrum, allowing for a reasonable
assignment of the apoHO-2 cross-peak from the hHO-2 spectrum, notably Leu-201 (Figure 11). Strikingly, of the 121 crosspeaks analyzed, the cross-peak at the location of Leu-201 in
the apoHO-2 spectrum is the most sensitive to the addition of
CPR, similar to what was observed for the hHO-2 spectrum.
Steady-state Kinetic Analysis of HO-1 and HO-2 Mutants — Residues that exhibit large changes in the hHO-2 NMR spectrum
upon binding CPR could be present at the interface of HO-2
and CPR, or alternatively, they could change their chemical environment due to long range conformational changes in
HO-2 induced by CPR binding at a distant site. Based on the
hypothesis that mutation of residues at the HO-2/CPR interface would lead to an increase in Kd values for the HO-2· CPR
complex and, thus, an increased Km value for CPR, we tested
the effect of alanine substitutions on steady-state kinetic parameters for Leu-201 and Lys-169, which were expected to exhibit higher Km values, and Arg-87, which was used as a control. If a residue exhibits changes in the NMR spectrum by
indirect effects (e.g. due to a conformational change), making
a conservative mutation of that residue is unlikely to affect the
Kd or Km values. Also, we note that HO-2 is likely a homodimer in the NMR binding studies. If a resonance is affected by
a change in HO-2 dimerization state, a mutation of that residue would be unlikely to affect the kinetic parameters of HO-2
and CPR.
Alanine substitution of the HO-2 residue with the crosspeak intensity that is most strongly affected by equimolar CPR in the non-perdeuterated NMR binding studies (Figure 9), L201A, results in a 3-fold increase in the Km for CPR
and no change in kcat compared with wild type protein (Figure
12B and Table 1). However, the R87A variant of HO-2, whose
NMR cross-peak height is not strongly affected by the addition of CPR, exhibits no change in the kcat or Km values for CPR
(Figure 12B and Table 1). These results are consistent with a
role for Leu-201 at the binding interface for CPR.
We also studied the K169A variant of HO-2 because alanine
substitution of Lys-149, the analogous residue in HO-1, exhibits a 7–10-fold increase in the Kd value of the HO-1· CPR complex (24, 27). We observe an ~20-fold increase in the Km value
of the K169A variant of HO-2 for CPR (Figure 12B, Table 1)
and a 40-fold increase in the Km value for the K149A variant of
HO-1 (Figure 12A and Table 1). These results indicate that this
lysine residue of HO-2 and HO-1 is involved in binding CPR.
Gel Filtration Analysis of the Binding of hHO-1, hHO-2, and CPR —
In an attempt to observe the complex between CPR and HO-2
(and HO-1) by other methods, we performed gel filtration experiments. Kd values ranging from ~0.5 to 2.0 μm have been reported for hHO-1 and CPR, and NADP+ is reported to enhance
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Figure 6. Effect of CPR on perdeuterated hHO-2 chemical shift intensities. Histogram bars represent the ratio of peak height in the absence or presence of CPR (+CPR/−CPR). Ratios with 75 and 150 μm CPR are shown (white and gray, respectively). A ratio of 1 (dotted line) indicates no change for that residue. Negative bars represent cross-peaks that are broadened beyond detection with the addition of CPR. Bars that are absent represent residues that are unassigned in the spectrum.

binding (24, 27). We performed gel filtration experiments with
50 μm HO-1 or HO-2 and equimolar CPR in the presence of
150 μm NADP+ and 150 μm heme. For comparison, the elution
of the individual proteins (HO-1, HO-2, and CPR) in the presence of heme and NADP+ was also determined. Because heme
or NADP+ could affect the migration of the individual proteins,
they were included in 3-fold excess in all samples.
By gel filtration analyses, we did not observe any evidence
for a complex between CPR and either hHO-1 or hHO-2 (Figure 13 and Table 2). CPR migrates at position 1 (~70 kDa)
in the absence (dashed line) or presence (red lines) of hHO-1
or hHO-2 (Figure 13). Peak 2, which marks the migration of
hHO-2 or hHO-1, corresponds to ~60 and 44 kDa, respectively,
and shows up as a shoulder in Figure 8A in the HO-1/CPR
sample. Consistent with the NMR relaxation studies, these results suggest that hHO-2 exists as a homodimer under these

conditions. The difference in apparent mass between HO-1
and CPR is greater than that between HO-2 and CPR; therefore, peaks 1 and 2 are slightly separated in Figure 13A and
are overlapped in Figure 13B. The elution profiles of CPR were
unaffected by incubation with either HO-1 or HO-2; for example, a CPR· HO-2 complex, which would have eluted at a position corresponding to ~100 kDa, was not observed. Others
have also failed to observe a complex between wild type HO-1
and CPR by gel filtration (26). The HO· CPR complex is undetected under these conditions, suggesting that the complex is
weak and/or highly transient, consistent with the NMR and
steady-state kinetic studies.
Binding of CPR to HO-1 or HO-2 by Surface Plasmon Resonance
(SPR) — We also attempted to quantify CPR binding to HO-1
and HO-2 using SPR, with HO-1 or HO-2 immobilized on the
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dextran surface of the SPR chip through amine chemistry (Figure 14). Representative association and dissociation curves
with various concentrations of CPR (1.25–20 μm) are shown
in Figure 14A. The SPR sensorgrams show CPR-dependent association and CPR-independent dissociation phases, clearly
demonstrating that CPR binds to both HO-1 and HO-2. To
avoid potential artifacts, these experiments were performed
in the absence of heme because heme itself produced a strong

Figure 7. CPR induced changes for hHO-2 cross-peak intensities
mapped onto the crystal structure. The effect of 75 or 150 μm CPR
(A and B, respectively) on hHO-2 cross-peak heights mapped on to the crystal structure of hHO-2 (PDB 2QPP). Cross-peak intensity ratios are as determined in Figure 6. The color of the residue reflects the degree of effect by
CPR. Red indicates ratio of 0 < 0.2; orange indicates ratio of 0.2 < 0.3; blue indicates ratio > 0.3; white indicates residues that are broadened beyond detection; gray indicates residues that are unassigned.
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“binding” response (Figure 14E). Use of the apoproteins is
justified by our NMR experiments (above) using apoHO-2
and CPR, which clearly demonstrate that CPR can bind both
apoHO-2 and hHO-2.
To derive binding kinetic constants from the SPR sensorgrams, the association and dissociation phases were fit individually because simultaneous global fitting analysis of CPR
association and dissociation curves using the 1:1 Langmuir
model (BIAevaluation) produces a poor fit to the data. Single
exponential fits of the association phase (GraphPad Prism6)
of CPR and HO-1 or HO-2 were used to determine kon values (0.0010 ± 0.0002 and 0.0014 ± 0.0002 s−1 μm−1) and koff values (0.020 ± 0.003 and 0.0230 ± 0.0003 s−1) for CPR binding to
HO-1 or HO-2, respectively (Figure 14, B and C). From these
kon and koff values, the Kd values of 20.5 ± 7.6 and 16.7 ± 2.5
μm were determined for CPR and HO-1 or HO-2, respectively,
indicating that these proteins form relatively weak (transient)
complexes. Biexponential fits of the dissociation curves (Figure 14D) indicate a fast and slow dissociation phase, with kfast
values in reasonable agreement with the values determined
by linear regression analysis of the binding data (kfast = 0.026 ±
0.002 and 0.035 ± 0.008 s−1; kslow = 0.0030 ± 0.0015 and 0.0025 ±
0.0005 s−1 for HO-1 and HO-2, respectively).
Sedimentation Velocity Analysis of HO-2 and CPR — Binding interactions between CPR and HO-2 were also analyzed by sedimentation velocity ultracentrifugation, a method that is less
sensitive to heme artifacts than SPR. As described under “Experimental Procedures,” 20.5 μm CPR was titrated with varying concentrations of heme-bound HO-2 (0–55 μm). In these
experiments, the sedimentation coefficient distribution of CPR
was monitored in the presence of increasing concentrations of
hHO-2. Figure 15A shows a sedimentation velocity profile obtained with a 2:1 molar ratio of hHO-2 to CPR. In the absence

Figure 8. NMR analysis of CPR binding non-perdeuterated 15N hHO-2. 1H-15N TROSY spectra of 150 μm non-perdeuterated 15N-hHO-2 collected in
the absence (black) or presence (red) of equimolar CPR.
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Figure 9. Effect of various concentrations of CPR on non-perdeuterated 15N-hHO-2 resonances. Histogram bars represent the ratio of resonance
height in the absence or presence of CPR (+CPR/−CPR). Ratios with 50, 150, 200, and 300 μm CPR are shown (black, light gray, dark gray, and white bars, respectively). A ratio of 1 (dotted line) indicates no change for that residue. Bars that are absent (gray labels) represent resonances that are unassigned, and assigned residues are in bold. The asterisk highlights Leu-201 as the cross-peak that is most sensitive to the addition of CPR.

of hHO-2, CPR is characterized by a sedimentation coefficient
centered at 4.5 S as shown in Figure 15B. hHO-2 alone shows
two sedimentation coefficients with a major component (60%)
centered at 2.8 S and a minor component (34%) at 4.2 S. Upon
adding hHO-2, the shape of the CPR component changes with
the boundary shifting to a higher sedimentation coefficient.
The weight-average s value of this fast boundary component
was determined by integrating the c(s) distribution between 4
and 7 S. From these data, a Kd of 15.1 ± 6.5 μm was determined
for hHO-2 and CPR. At the highest hHO-2 concentration, the
CPR·HO-2 complex was characterized by a weight-average s
value of 5.2 S.
Chemical Cross-linking of CPR and HO-1 or HO-2 — We conducted chemical cross-linking experiments to trap the complex between HO-2 and CPR. Because cross-linking is an irreversible reaction, even transient complexes can be detected.

Because CPR has been reported to bind HO-1 (24–27), we used
HO-1 and CPR as a positive control. According to the crystal structure (PDB 3QE2), human CPR possesses at least two
surface cysteine residues, which should be available for crosslinking. Thus, we utilized the heterobifunctional cross-linker
LC-SPDP, which contains both an amine and a thiol-reactive
group. As described under “Experimental Procedures,” after activating HO-1 or HO-2 and removing unreacted crosslinker, CPR was added, and the reaction was incubated overnight at 4 °C. Stable complexes between CPR and HO-1 as well
as CPR and HO-2 were formed (Figure 16A). A small amount
of HO-2 homodimer is visible in the HO-2 sample that lacks
CPR, although, for activated HO-1 alone, no homodimeric
complex was observed.
As a negative control, we activated the HOs as described
above and incubated with a physiologically unrelated cysteine-containing protein, RNase, instead of CPR. RNase (based
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Figure 10. NMR analysis
of CPR binding apoHO-2.
1H-15N TROSY spectra of 500
μm non-perdeuterated 15NapoHO-2 collected in the absence (black) or presence (red)
of 100 μm CPR.

Figure 11. TROSY spectra of hHO-2 (black) and
apoHO-2 (red). 1H-15N
TROSY spectra of 150 μm
non-perdeuterated15N-hHO-2
(black) or 500 μm non-perdeuterated apoHO-2 (red). The
cross-peak assigned as Leu201 for the hHO-2 spectrum is
identified.

on PDB 1RCA) contains eight cysteine residues, four of which
are surface-exposed. No high molecular weight complex between RNase A and either HO-1 or HO-2 was observed (Figure 16B).
NMR Studies of HO-2 in the Presence of BVR — BVR mediates
the second step in heme degradation, the conversion of biliverdin to bilirubin. HO-1 and BVR are reported to form a complex with a Kd of 0.2 ± 0.1 μm (24, 27). An overlapping binding site on HO-1 for CPR and BVR has been proposed but with
the binding sites not identical (24, 25, 27). To our knowledge,
binding of HO-2 and BVR has not been addressed.
To attempt to characterize the binding interface between
HO-2 and BVR, we performed NMR experiments similar to
those described for HO-2 and CPR. The 1H-15N TROSY spectrum of 150 μm non-perdeuterated 15N-hHO-2 was collected
in the absence or presence of equimolar BVR (not labeled with

15N).

Although CPR induced obvious changes in the hHO-2
spectrum (Figure 8), the spectrum of hHO-2 collected in the
presence of BVR is almost identical to that of hHO-2 alone
(Figure 17). No changes in the chemical shifts are apparent,
and the majority of assigned resonances exhibit a height ratio (+BVR/−BVR) close to 1, indicating no change (Figure 18).
These results suggest that under the NMR conditions (150
μm), BVR binds hHO-2 very weakly, if at all. Experiments
with 15N-apoHO-2 and equimolar BVR also showed BVR has
no effect on the apoHO-2 spectrum (data not shown).
Our NMR binding studies thus suggest that BVR has a
significantly lower affinity for HO-2 compared with CPR. In
contrast, others have reported nanomolar Kd values for the
BVR·hHO-1 complex (27). Because HO-1 and HO-2 are highly
homologous, our results were unexpected. Thus, other experiments were performed to assess the interaction between the
HOs and BVR.
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Figure 12. HO mutants have an increased Km values for CPR. Heme
oxygenase activity for HO-1 (A) or HO-2 (B) and their respective mutants
with varying amounts of CPR. Activity was monitored by observing the formation of bilirubin at 468 nm, as described under “Experimental Procedures.”
Table 1. Michaelis parameters for HO variants and CPR. Heme
oxygenase activity was monitored for HO-1 or HO-2 and the indicated
mutants with varying amounts of CPR as shown in Fig. 12. Specific activity is
represented as nanomoles of bilirubin/min/mg of HO.
Construct
HO-1
WT
K149A
HO-2
WT
R87A
L201A
K169A

Vmax
nmol min–1 mg–1

Km
μM

Km
-fold change

370± 12
847 ± 64

0.5 ± 0.1
21.7 ± 2.6

1
42.4

296.9 ± 4.6
275 ± 11
298.2 ± 8.0
417 ± 37

0.7 ± 0.1
0.9 ± 0.1
2.3 ± 0.2
15.2 ± 2.6

1
1.3
3.3
21.7

Fluorescence Quenching Experiments Involving BVR-CPM and HO-1
or HO-2 — One possible explanation for the lack of NMR evidence for an HO-2/BVR interaction is that HO-2 interacts
differently with BVR compared with HO-1. To address this
possibility, we repeated the published fluorescence quenching experiments for measuring interactions between HO-1
and BVR (27), and we performed similar experiments to determine the binding affinity of HO-2 for BVR. In these studies, BVR was labeled with the thiol-reactive dye CPM to produce fluorescent BVR upon excitation at 350 nm. Because the
hHO-1 absorption spectrum overlaps with the emission spectrum of BVR-CPM, hHO-1 binding results in fluorescence
quenching due to FRET processes. Because apoHO has no absorbance in the 350 nm region, this method can only be used
to evaluate hHO binding. Plotting the % fluorescence quenching at 455 nm versus hHO-1 concentration produced a binding
curve (Figure 19A) that fits to a one-site binding model with
a Kd of 0.25 ± 0.09 μm, almost identical to the previously reported value of 0.22 ± 0.09 μm (27). Similar FRET experiments
with hHO-2 and BVR (Figure 19B) provided concentration-dependent, saturable binding curves with a Kd of 0.27 ± 0.01 μm.

Figure 13. HO and CPR analysis by size exclusion chromatography.
50 μm CPR and HO-1 (A) or CPR and HO-2 (B) were loaded onto a Shodex
KW-803 gel filtration column individually or in the indicated mixture in the
presence of 150 μm heme and 150 μm NADP+ in running buffer (50 mm Tris,
50 mm KCl, pH 7.0). The asterisk represents the retention time for a 100kDa protein, and gray arrows mark the position of the molecular weight standards. Peak 1, CPR; peak 2, heme oxygenase; peak 3, NADP+ and heme; peak
4, HO-2 aggregate.
Table 2. Apparent molecular weight of HO-1, HO-2, and CPR by
gel filtration. Ve/V0 values for the indicated proteins, blue dextran (V0), B12,
and protein standards (Bio-Rad) were measured, and the apparent masses
were determined as described under “Experimental Procedures.”
Protein
Ve/V0
Apparent mass
		Da
HO-1
HO-2
CPR
CPR (with HO-1)
CPR (with HO-2)

1.565 ± 0.005
1.525 ± 0.002
1.509 ± 0.004
1.507 ± 0.004
1.506 ± 0.002

44,000 ± 1600
60,300 ± 1100
68,600 ± 2000
69,600 ± 2000
70,000 ± 1300

These results suggest that BVR binds both HO-1 and HO-2
with similar high affinity. Equation 3 can be used to estimate
a Kd value in situations where the concentration of free ligand
cannot be estimated due to high affinity and near stoichiometric binding. If HO-2 and BVR have a Kd of ~300 nm (as suggested by the fluorescence quenching results), Equation 3 predicts 70% of HO-2 should be complexed with BVR under the
NMR conditions (with 150 μm HO-2 and 150 μm BVR). This
is clearly inconsistent with the NMR results; therefore, we
conducted additional experiments to interrogate the source
of this apparent discrepancy between the NMR and FRET
experiments.
1

EL = 0.5 (E0 + L0 + Kd – ((E0 + L0 + Kd)2 – 4 E0 ∙ L0) /2)

(3)

Fluorescence Quenching of BVR-CPM by Heme — To attempt
to resolve the inconsistency between the NMR and fluorescence quenching results, we tested the hypothesis that free
heme, dissociating from HO-2, may be responsible for the
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Figure 14. SPR analysis of CPR biding HO-1 (left panels) and HO-2
(right panels). A, various concentrations of CPR (1.25, 2.5, 5.0, 10.0, and
20.0 μm) were injected against immobilized HO-1 or HO-2. B, single exponential fits for the association phase of CPR binding HO-1 or HO-2 are
shown in red. C, single exponential fits were used to determine kobs for the
association phase of CPR binding HO-1 or HO-2. kon and koff values are derived from the linear regression of kobs (kon = slope; koff = y intercept). D, biexponential fits for the dissociation phase of CPR binding HO-1 or HO-2
are shown in red. E, various concentrations of heme (0.125, 0.25, and 0.5 μm)
were injected against immobilized CPR. Data are representative of three independent experiments.

fluorescence quenching of BVR-CPM. When free heme was titrated into BVR-CPM under conditions identical to those used
for hHO titrations, there was strong concentration-dependent
and saturable quenching of BVR-CPM fluorescence (Figure
19C), indicating a Kd value of 0.037 ± 0.01 μm. These results
suggest that the fluorescence quenching observed in the FRET
experiments could be due to the effects of heme binding to
BVR, or the CPM fluorophore, rather than the HO protein. Assuming a Kd of 33 nm for HO-2 and heme (17), Equation 3 predicts that 1 μm hHO-2 will contain ~0.17 μm dissociated heme,
which is well above the Kd value determined in these experiments. Thus, we suggest that the quenching of BVR-CPM
fluorescence observed in the titration with hHO-1 or hHO-2
results from free heme, dissociated from HO, not the HO protein. We propose that the heme binds to BVR-CPM from solution and not through direct heme transfer from the heme-HO
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Figure 15. Sedimentation velocity analysis of HO-2 and CPR interactions. A, velocity scans selected from analysis of a 2:1 ratio of hHO-2 (41
μm) to CPR (20.5 μm). Shown are the absorbance data (open circles) fitted
(solid lines) to the continuous c(s) distribution model. B, sedimentation coefficient distributions of CPR (20.5 μm) alone (black trace) and in the presence of 4.1 μm (brown trace), 10.25 μm (blue trace), 20.5 μm (red trace), 30.75
μm (purple trace), 41 μm (green trace), and 55 μm HO-2 (gray trace). hHO-2
alone (41 μm) is shown in magenta. The inset shows the weight-average s
value plotted versus HO-2 concentration. The data were fit to a single-site
binding isotherm to yield a Kd value of 15.1 ± 6.5 μm.

complex to BVR. In fact, our results demonstrate that these
proteins do not form a complex, dispelling the possibility of a
protein-to-protein heme transfer.
The effects of free heme on BVR-CPM fluorescence are consistent with the report that heme binds to BVR and to residues
290–296 of the BVR C-terminal peptide (KYCCSRK) (36). Furthermore, when we analyzed BVR-CPM by LC MS/MS to determine the location of the CPM label, we identified one CPM
molecule attached to Cys-204 and another to either Cys-292 or
Cys-293 of BVR (Figure 20). Because Cys-292 and Cys-293 are
located on the same peptide in the LC MS/MS analysis, the
two cysteines were not distinguished by this analysis.
Although the other surface-exposed Cys (Cys-74) is not observed in this analysis, it is most likely unmodified because
BVR-CPM has enzymatic activity similar to that of the wild
type protein (109%). We and others (59) find that mutation of
Cys-74 in human BVR, or its homolog Cys-73 in rat BVR, ablates enzymatic activity. Additionally, CPM labeling was conducted in the presence of NADP+, which is expected to protect
the enzymatic cleft from modification.
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with increasing concentrations of BVR titrated into hHO-2, absorbance at 415 nm also increases. This result supports that
BVR is capable of binding heme from hHO-2 (Figure 21C).

Figure 16. Chemical cross-linking of HO-2 and CPR. A, heterobifunctional cross-linker LC-SPDP stabilizes a complex between HO-1 or HO-2
and CPR. B, no complex is trapped for HO-1 or HO-2 with RNase. C, chemical cross-linking also stabilizes a complex between HO-1 or HO-2 and BVR.
Cross-linking reactions contained 10 μm of the indicated protein. D, reducing
SDS-PAGE and Western blot of HO-2 pulldown and associated BVR. Lane 1,
cross-linking reaction; lane 2, HO-2 only; lane 3, BVR only.

BVR Binding Heme by Optical Absorbance — To further investigate the possibility that the fluorescence quenching of BVRCPM by hHO-2 results from the binding of free heme by BVR,
we titrated BVR with free heme and measured the absorbance
spectrum. As observed by others (36), BVR alone shows no optical absorbance in the 350–700 nm range; however, in the presence of heme, we observe the development of an absorbance
band with a wavelength maximum at 415 nm, indicating that
free heme binds BVR (Figure 21A). To determine the affinity of
heme for BVR, 5 μm heme was titrated with BVR, and the absorbance at 415 nm was measured and fit to a single-site binding model, yielding a Kd of 220 ± 50 nm (Figure 21B).
Titration of BVR-CPM with hHO-2 produces strong fluorescence quenching; however, because there is no evidence of
HO-2/BVR binding by NMR, we hypothesize that heme, not
HO, is responsible for a large part of the fluorescence quenching. To test whether heme from hHO-2 can bind BVR, we incubated hHO-2 with BVR. Because the absorbance of hHO-2
is ~10-fold greater than that of heme-bound BVR and because
the absorbance spectra overlap, hHO-2 was included in the
reference cuvette for these titrations. Under these conditions,

Chemical Cross-linking of HO-2 and BVR — The above results
suggest that HO-2 and BVR either do not interact or that that
they form a very weak complex. We incubated HO-2, which
had been activated with LC-SPDP and with BVR, as described
above for trapping the HO-2· CPR complex. Because HO-1
and BVR have been reported to form a complex (24, 27), we
also conducted the experiment with HO-1 as a positive control. Under conditions identical to those used to stabilize the
HO-2· CPR complex, a high molecular mass complex of ~60
kDa was observed by SDS-PAGE for BVR and both HO-1 and
HO-2 (Figure 16C).
Because HO-2 and BVR are similar in molecular mass, a
heterodimer of HO-2 and BVR is not distinguishable from either homodimer by size alone. To determine whether BVR is
directly linked to HO-2 in the cross-linked product, we conducted the cross-linking reaction using HO-2 that retained
an N-terminal His6 tag (hisHO-2). The cross-linked products
with hisHO-2 were identical to those with HO-2 by SDS-PAGE
analysis (data not shown). We then isolated hisHO-2 from
the cross-linking reaction using Ni-NTA resin and analyzed
the proteins that associated with the affinity resin by reducing SDS-PAGE, which was subjected to Western blotting using antibodies against HO-2 or BVR. Under these conditions,
the cross-linker undergoes reduction, allowing the proteins to
migrate at their native size. BVR was found to copurify with
HO-2 in the cross-linked product (Figure 16D). A control reaction demonstrated that BVR alone did not associate with the
affinity resin (Figure 16D). These results demonstrate that an
HO-2·BVR complex can be trapped by chemical cross-linking.
To identify the location of the cross-linker in the HO-2·BVR
complex, we conducted a tryptic digest followed by LC-MS/
MS analysis of the cross-linked product. This analysis identified
the HO-2 peptide containing Lys-264 (KCPFYAAEQKD) linked
to the BVR peptide containing Cys-292 and Cys-293 of BVR
(YCCSR), the same peptide shown earlier to bind heme (36).
Discussion
In the HO reaction, seven electron equivalents from NADPH
are transferred to the HO-bound heme via CPR. For rapid
and efficient electron transfer, the electron donor (flavin on
CPR) and acceptor (heme of HO-2) should be at optimal orientation and distance, implying that an electron transfer complex is formed during the catalytic cycle. One of the issues we
have addressed in this paper is the existence and nature of that
electron transfer complex. One possibility is that HO and CPR
form a stable complex within which multiple electrons transfer
from NADPH through the bound flavins (FAD and FMN) on
CPR to the HO-bound heme as it undergoes oxygenation and
conversion to biliverdin and CO. The other possibility is that
HO and CPR encounter each other only transiently and associate/dissociate multiple times during each catalytic cycle. Similarly, either HO or BVR forms a stable complex, within which
biliverdin is transferred (perhaps channeled) between the two
proteins or, as another alternative, remains completely unattached as the HO product (biliverdin) is released into solution and captured by BVR to undergo conversion to bilirubin.
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Figure 17. NMR analysis of BVR binding HO-2. 1H-15N TROSY spectra of 150 μm non-perdeuterated
presence (red) of equimolar BVR.

Based on fluorescence quenching, SPR and acetylation protection studies, a moderately tight HO-1·CPR complex with a Kd
value in the ~1 μm range had been identified. However, SPR,
fluorescence quenching, and acetylation protection assays with
HO-1 have yielded inconsistent results regarding which residues form the HO-1/CPR binding interface (24, 25, 27).
Interactions between HO and CPR — Whether or not HO-2 and
CPR form a complex has not been previously investigated. As
a result of spectroscopic (NMR, fluorescence), steady-state kinetic, and other biochemical (chromatographic, analytical centrifugation, and SPR) studies, we have obtained novel information about the nature of the interactions between these two
proteins.
Although our focus is on HO-2, we also analyzed CPR
binding to HO-1, primarily as a positive control for the HO-2/
CPR studies, as CPR binding HO-1 has been previously described (24–27). Consistent with previous reports, we observe
CPR binding HO-1 by SPR and by chemical cross-linking.
By gel filtration experiments, under our experimental conditions (50 μm hHO and 50 μm CPR with NADP+), HO-2 appears to form a homodimer. We do not observe any evidence
for a complex between HO-2 and CPR. Gel filtration experiments occur under nonequilibrium conditions in which the
component proteins of any transient complex, once dissociated from the complex, are unable to reassociate once they are
in a separate zone of the chromatographic column. However,
SPR experiments clearly demonstrate CPR binding to HO-2
(Figure 14).
SPR is a valuable method for studying protein-protein interactions because the proteins remain in the same solution
and reach equilibrium; furthermore, one can monitor both the

15N-hHO-2
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collected in the absence (black) or

rates of association and dissociation. Our SPR results clearly
demonstrate that CPR binds to both HO-1 (Kd = 20.5 μm) and
HO-2 (Kd = 16.7 μm) with CPR-dependent rates of association
and CPR-independent dissociation rates. For HO-1, our results
give a Kd value that is 10-fold larger than previously reported
(24). The lower affinity of CPR for HO-1 observed in our studies could be due to differences in the experimental design; our
studies were conducted in the absence of heme and utilized
immobilized HO-1 with human CPR as the soluble analyte,
whereas earlier studies were conducted with immobilized
rat CPR with hHO-1 in solution. Although we also observe
a binding response when we titrate either hHO-1 or hHO-2
against immobilized human CPR, we found that free heme
also produces a strong binding response with immobilized human CPR (Figure 14E) and with immobilized BVR (data not
shown). Thus, to avoid potential artifacts, these experiments
were performed in the absence of heme. Our use of the apoHOs is justified by our NMR experiments, which clearly demonstrate that CPR can bind both forms (apoHO-2 and hemebound) of HO-2. We are unaware of any physiologic rationale
for heme binding to CPR, so this is likely to be a nonspecific effect. However, as we discuss below, BVR has previously been
shown to bind heme and to shuttle heme into the nucleus (36).
Although by SPR we observe no binding of apoHO to immobilized CPR, the conformation of CPR is critical for HO binding (26), and it is possible that immobilization of CPR stabilizes a conformation that has a lower affinity for HO.
Sedimentation velocity experiments also provide evidence
of a dynamic complex between HO-2 and CPR, with a Kd (15.1
μm) value that is similar to that calculated from the SPR data.
The HO-2· CPR complex can also be captured by chemically
cross-linking an amino group of HO-2 through a 15.7 Å tether
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Figure 18. Effect of BVR on HO-2 resonances. The ratio of hHO-2 resonance height with and without equimolar BVR (+BVR/−BVR) is represented by the
gray bars. A ratio of 1 (dashed line) indicates no change for that residue. Bars that are absent (gray labels) represent resonances that are unassigned, and assigned
residues are in bold.

to a surface-reactive Cys residue on CPR. The latter is, of
course, irreversible and designed to capture even highly transient interactions.
The NMR experiments also show that an interaction between HO-2 and CPR occurs. The primary proof is the overall and large loss of peak intensity for the core resonances,
due to broadening associated with the large increase in timeaveraged molecular weight. In addition, excess peak intensity loss due to exchange broadening and CSP occurs for several but not all signals. The latter observations are compatible
with specific binding and with binding kinetics that are on
the fast/intermediate NMR shift time scale (koff ~100 s−1). In
turn, this is suggestive of a Kd value in the low micromolar
range, consistent with the values of 15 μm as found by analytical ultracentrifugation experiments and 16.7 μm as found
by SPR. Regretfully, the NMR experiments do not allow a precise determination of these values, because the NMR signals

disappear at higher titration stoichiometries, and saturation of
binding cannot be observed.
Having assigned ~70% of the resonances in the HO-2 NMR
spectrum, we used the CSPs to identify the HO-2/CPR interface. Titration of perdeuterated 15N-hHO-2 with CPR altered
the chemical shift of several residues in the hHO-2 NMR spectrum. At both 75 and 150 μm CPR, residues of the HO-2 catalytic core exhibit larger CSPs compared with the N and C termini (Figure 4). Residues that exhibit the largest CSPs with the
addition of 75 μm CPR are Phe-99, Tyr-202, Leu-66, Lys-89,
and Glu-190.
Upon adding CPR, we also observed dramatic and titratable reductions in the intensities of some of the 1H-15N TROSY
peaks of resonances from the catalytic core domain of HO-2
(Figs. 6 and 9). The majority of intensity changes due to exchange broadening of the TROSY peaks occur in the structured core region of HO-2, with few intensity changes
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Figure 19. Fluorescence quenching of BVR-CPM by heme oxygenases and heme. Titration of heme-bound HO-1 (A), HO-2 (B), or heme
alone (C) into BVR-CPM. Percent fluorescence quenching plotted against the
concentration of the titrant and fit to a single binding model to determine
the Kd of binding using GraphPad Prism 6.0.

Figure 20. Biliverdin reductase modified by CPM. LC-MS/MS analysis
of BVR-CPM identifies CPM modification (*) at Cys-280 and either Cys-292
or Cys-293. Cys-74 was not observed in this analysis.

originating from the dynamically unfolded N (Ser-8) or C terminus (Tyr-268). Chemical shift perturbations induced by CPR
titrations also affect the core residues of hHO-2, although the
N and C termini are unaffected (Figure 4). These results indicate that CPR interacts with the catalytic core of the protein
and has minimal interactions with the N- or C-terminal regions of HO-2.
Figure 22A highlights residues on hHO-2 that exhibit both
significant CSPs and large intensity changes with the addition
of 75 μm CPR as follows: Leu-66, Phe-99, Glu-102, Asp-193,
Gln-200, Tyr-202, and Leu-209. Strikingly, in the recent HO-1/
CPR crystal structure, residues conserved with HO-2, Phe-99,
Glu-102, Gln-200, and Tyr-202 form a patch that is at the CPR
interface (Figure 22B). The HO-1 residue conserved with Asp193 is also located at the CPR interface, as are HO-1 residues
conserved with the HO-2 residues targeted by mutagenesis,
Leu-201 and Lys-169 (Figure 22).
Additional HO-2 residues show either significant CSPs without extra intensity change or large changes in intensity without chemical shift changes. Especially the latter phenomenon

Figure 21. Heme binds BVR by optical absorbance. A, absorbance
spectrum of 2.5 μm BVR with 2.0 μm heme. BVR alone shows no absorbance in the 350–700 nm range. B, A414 of 10 μm heme titrated with varying
concentrations of BVR (0.05, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.2, 2.0, 3.0, and 5.0 μm
BVR). Data are fit to a single binding model using GraphPad Prism 6.0. C, 5
μm hHO-2 alone (dotted line) or titrated with various concentrations of BVR
(1.0, 2.0, 8.0, 10.0, and 20.0 μm). Samples for BVR titrations contain 5 μm
hHO-2 in the reference cuvette because the absorbance of hHO-2 is ~10fold that of heme-BVR, and the hHO-2 spectrum overwhelms the heme-BVR
spectrum if it is not subtracted.

is prevalent for the most affected residue, Leu-201, and is theoretically incompatible with a canonical intermediate exchange
binding process as described by Equation 2. Rather, it is suggestive of additional, significantly populated bound states of
CPR sensed by Leu-201 that are in intermediate/fast exchange
with each other and with Leu-201 in the free state. It can be
shown that the observed broadening without shift can occur
if the CSPs of the different bound states approximately cancel. (E. R. P. Zuiderweg, unpublished data.) The residues affected by this noncanonical mechanism are conserved in HO1, where they are located at the interface for CPR (Glu-86,
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Figure 22. Interface for CPR on HO-2 defined by NMR and mutagenesis. A, residues in red have both significant CSPs and large intensity ratio changes
with the addition of 75 μm CPR. Residues of HO-2 that have significant CSPs or large changes in peak intensity ratio with the addition of 75 μm CPR are shown
in orange. { identifies a patch of residues strongly affected by CPR (Phe-99, Glu-102, Gln-200, Leu-201, and Tyr-202). Leu-201 and Lys-169 were identified by mutagenesis. Side chains are shown as spheres (PDB 2QPP). B, residues identified for HO-2 mapped onto the analogous residues of HO-1 in the published crystal
structure of the complex of rat HO-1 (gray) and rat CPRΔTGEE (yellow) (PDB 3WKT). Cofactors are as indicated as follows: heme (green), NADP+ (blue), FAD
(purple), and FMN (orange).

Asp-90, Glu-190, Leu-201, Arg-203, Ala-208, and Asp-210) or
in patches of residues adjacent to the interface in (Ala-31, Leu33, Leu-36, Leu-37, Leu-81, Glu-107, Lys-89, Asn-88, Leu-149,
Gln-172, Glu-182, Thr-184, and Thr-215). These residues also
localize at and around the binding site for HO-2 as identified
from CSPs alone. The extended nature of the interaction surface would also be compatible with multiple binding modes
for CPR as implied from the noncanonical broadening. The existence of multiple bound states, or an ensemble of encounter
complexes, has been suggested for other electron transfer complexes as well (60, 61).
NMR relaxation and gel filtration studies indicate that
HO-2 exists as a homodimer in solution at the conditions
used. Changes in the homodimerization state of HO-2 upon
CPR binding could give rise to CPR-dependent changes in the
TROSY spectrum, and these changes would be difficult to distinguish from changes induced by CPR binding HO-2 directly.
However, HO-2 crystallizes as a homodimer, and the HO-2/
HO-2 interface is distant from the majority of the CPR-induced
changes that occur in the HO-2 TROSY spectrum (Figure 22A).
This supports that the CPR-induced changes observed in the
HO-2 TROSY spectrum are not due to changes in the HO-2 dimerization state but rather CPR directly binding to HO-2.
There is a major difference between the koff as suggested by
NMR (~100 s−1) and the value measured by SPR (~0.023 s−1).
The latter value would give rise to an extremely slow NMR
shift time scale and would not allow for any of the observed

chemical shift changes. This contradictory situation is reminiscent of the binding of an organic phosphate molecule to hemoglobin, where, despite an off-rate of 0.01 s−1, fast exchange
dynamics were observed using 31P NMR. Multiple binding
sites for the small molecule on the hemoglobin surface were
proposed to explain the apparent discrepancy, and a mathematical model that recapitulated the experimental results was
described (62, 63). In this study, we have evidence for the existence of multiple bound states of CPR. Perhaps the observed
rate of ~100 s−1 as indicated by NMR is reflective of the exchange kinetics between the various bound states. In contrast, the off-rate as measured by SPR monitors the complete
dissociation.
Although previous reports on the HO-1· CPR complex focus on charge-charge interactions (from residues that we were
not able to assign in our NMR spectra), our results provide the
first evidence that hydrophobic residues may be involved in
HO/CPR binding. The majority of the residues highlighted in
the NMR binding studies are involved in interacting with the
FAD binding domain of CPR (Figure 22). Kinetic results discussed below concur with these NMR results.
Our steady-state kinetic analyses support the conclusion
that the area near the exposed heme binding face in the catalytic core of HO-2 is involved in binding CPR. For example, HO-1 and HO-2, which share a high degree of structural
similarity in their catalytic core region (55), exhibit similar Km values for CPR (0.5–0.7 μm). Furthermore, alanine
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substitution of the core residues that are proposed to be at
the HO/CPR interface, Lys-169 (or Lys-149 in HO-1) and
Leu-201, results in significant increases in the Km value for
CPR. K169A, for example, exhibits a 20-fold increase in Km
for CPR, in close agreement with prior SPR (24) and acetylation protection assays (25) but in contrast with earlier FRET
measurements, which showed no effect of Ala substitution at
that site (27). The K169A variant of HO-2 also exhibits a 1.4fold increase in Vmax, and the K149A variant of HO-1 exhibits
a 2.2-fold increase in Vmax suggesting that lowering the affinity for CPR increases the steady-state rate under saturating
substrate (NADPH, O2, and CPR) concentrations. That the
K149A variant binds heme with identical affinity as the wild
type (24) and does not exhibit a decrease (instead a slight increase) in Vmax supports our conclusion that its increase in Km
for CPR reflects disruption of a key interaction between CPR
and HO-2, not some major disruption in the overall structure
or at the active site.
The HO reaction involves many steps, including heme
binding, seven steps of electron transfer, 3 mol of oxygen
binding, oxygen activation, biliverdin release, etc. It is accepted that the rate-limiting step in the HO-1 catalytic cycle when BVR is present is the ring opening of Fe(II)-verdoheme (40, 64). However, it is possible that this lysine variant
is rate-limited by another step. The details of the catalytic cycle for HO-2 or for this variant have not been characterized.
However, given that K149A (HO-1) and K169A (HO-2) exhibit a 1.4–2.2-fold increase in Vmax and a 20–40-fold increase
in Km for CPR, it seems reasonable to speculate that, at saturating concentrations of CPR, the rate-limiting step for this lysine
variant is electron transfer from CPR to the heme.
Taken together, our results suggest that during the multistep HO-2 reaction, a transient complex between HO-2 and
CPR forms and dissociates rapidly and that the productive
electron transfer complex includes HO-2 residues Leu-201
and Lys-169. The transient nature of the interactions between
HO-2 and CPR is likely to be an important catalytic feature,
especially in this and other systems where multiple electrons
must be passed during each catalytic cycle.
Our results indicate that a similar dynamic and transient
binding scenario exists with HO-1. Our gel filtration and SPR
results indicate that HO-1 (like HO-2) forms a rather weak
complex with CPR. The transient nature of these interactions
between HO and CPR is likely to be important in the HO
mechanism, which requires seven electrons to be transferred
from NADPH through the redox centers on CPR.
The catalytic core, shown clearly to be the domain of HO-2
that interacts with CPR, is highly homologous with HO-1. For
example, catalytic core residues with NMR resonances most
strongly affected by CPR that exhibit both CSPs and broadening (Leu-66, Phe-99, Glu-102, Asp-193, Gln-200, Tyr-202, and
Leu-209) or with binding constants affected by mutagenesis
(Lys-169 and Leu-201) are highly conserved between HO-1
and HO-2. All of those residues are strictly conserved except
Leu-66 (Gly-46 in HO-1). Earlier reports identified Lys-149 of
HO-1 to be important in binding CPR (24, 25). It was shown
that CPR prevents acetylation of that Lys residue and that substitution of Ala at that position results in a 7-fold decrease in
affinity for CPR. We found that the K149A substitution results
in a 40-fold increase in Km for CPR (20-fold for the analogous
K169A mutation in HO-2). Thus, it appears that both HOs interact similarly with CPR.
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Our results support that HO-2 forms a highly dynamic
complex with CPR at an interface that includes HO-2 residues
Leu-201 and Lys-169, and the CPR interface is likely highly
conserved for both HO-1 and HO-2. As shown in Figure 22B,
the homologous residues in HO-1 (Leu-181 and Lys-149) are
located at the HO-1/CPR interface in the crystal structure of
a complex between HO-1 and a deletion variant of CPR (CPR
ΔTGEE) (26). This CPR variant forms a stable complex with
HO-1 that, unlike the wild type protein, can be observed even
by gel filtration (26). Given the high homology of the structures of the catalytic cores of HO-1 and HO-2 (55), we suggest
that Leu-201 and Lys-169 of HO-2 participate in stabilizing the
electron transfer complex between HO-2 and CPR.
Interactions between HO and BVR — Based on prior fluorescence quenching studies, HO-1 and BVR were proposed to
form a high affinity complex (27), and our goal was to characterize the analogous HO-2·BVR complex using various biochemical and biophysical methods. However, addition of BVR
to 15N-labeled hHO-2 results in no chemical shift perturbation and, of the 104 assigned resonances in the hHO-2 spectrum, only five exhibit a BVR-dependent decrease in intensity.
Of those residues that exhibit sensitivity to BVR, three are on
the surface of the crystal structure and could reasonably be involved in binding BVR (Lys-176, Gln-196, and Tyr-229) (Figure 18). In contrast, under the same conditions with equimolar
CPR, 48 of the assigned HO-2 resonances exhibit strong CPRdependent effects (Figure 9). These results suggest BVR binds
hHO-2 with a weak affinity compared with CPR.
Because the TROSY experiments indicated that HO-2 does
not bind BVR with high affinity (Figure 18), we repeated the
original fluorescence quenching studies that described the
hHO-1· BVR complex (27). Although our results with hHO-1
are nearly identical to those described in the original paper,
additional controls indicate that free heme strongly quenches
BVR-CPM fluorescence independently of HO. We also used
optical absorbance methods to verify the ability of BVR to
bind heme, as was reported previously (36). The Kd value
for the heme· BVR complex differs between the two experiments, with the absorbance data indicating binding of more
than heme to BVR. Furthermore, labeled BVR contains fluorophores at two specific sites (Cys-292 or Cys-293 and Cys-204).
We suggest that the fluorescence quenching studies may monitor binding of one heme to BVR at a high affinity site near one
of these fluorophores, although the optical absorbance studies
may reflect multiple heme binding events.
Thus, the fluorescence quenching studies aimed at studying interactions between HO-2 and BVR actually report on
binding of heme in solution that has dissociated from hHO,
rather than direct interactions between hHO and BVR. In fact,
detection of an HO· BVR complex requires the use of methods
like chemical cross-linking, where even transient complexes
can be trapped.
This result describing the low affinity of HO for BVR is important because it clarifies the mechanism by which BVR couples to the HO reaction. It has been shown that BVR changes
the rate-limiting step of the HO-1 reaction from biliverdin release to the conversion of the Fe2+-verdoheme intermediate to Fe3+-biliverdin (40). We had taken this to indicate the
possibility that biliverdin is channeled between the two proteins. However, it now appears that the effect of BVR on the
HO rate-limiting step occurs by kinetic coupling of the HO
and BVR reactions, not substrate channeling. BVR binds HO-2
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very weakly; therefore, substrate channeling, which requires a
stable complex, is unlikely. Thus, BVR simply binds the biliverdin upon release from its product complex with HO, enhancing the HO reaction by affecting the mass balance.
Conclusions — In conclusion, we show that protein· protein
complexes between HO-2 and other proteins in the heme degradation pathway (CPR and BVR) are highly transient. HO-2
and CPR form a transient electron transfer complex and, like
other electron transfer pairs, HO-2 and CPR may form an ensemble of complexes that is in equilibrium with the productive
electron transfer complex. NMR binding studies and mutagenesis of HO-2 highlight an interface for CPR on HO-2, which is
consistent with what has been described for CPR and HO-1.
However, in contrast to studies with CPR and HO-1, our results suggest that CPR binding HO-2 in solution is dynamic.
Gel filtration and ultracentrifugation studies support a weak/
transient CPR· HO-2 complex. Complex formation between
HO-2 and BVR is undetected, except via irreversible binding
(cross-linking) methods. In the cell, CPR is an electron donor
for many biologically important reactions. The dynamic interactions between CPR and HO-2 revealed in these studies may
play an important role in the regulation of the HO system in a
cellular context.
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